50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
NASDAQ:INCY

Incyte - INCY Stock Forecast, Price & News

$66.44
+0.26 (+0.39%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$65.88
$67.53
50-Day Range
$66.18
$82.86
52-Week Range
$61.91
$84.86
Volume
1.80 million shs
Average Volume
1.25 million shs
Market Capitalization
$14.78 billion
P/E Ratio
15.63
Dividend Yield
N/A
Price Target
$84.92

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
27.8% Upside
$84.92 Price Target
Short Interest
Bearish
3.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.01mentions of Incyte in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$589,387 Sold Last Quarter
Proj. Earnings Growth
36.73%
From $2.45 to $3.35 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.01 out of 5 stars

Medical Sector

35th out of 1,071 stocks

Commercial Physical Research Industry

2nd out of 16 stocks

INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

Incyte (NASDAQ:INCY) Lowered to "In-Line" at Evercore ISI
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings
8/02/2022
Today
9/27/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,094
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$84.92
High Stock Price Forecast
$108.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+27.8%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$948.58 million
Pretax Margin
18.95%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$2.39 per share
Book Value
$17.07 per share

Miscellaneous

Free Float
183,506,000
Market Cap
$14.78 billion
Optionable
Optionable
Beta
0.66

Social Links


Key Executives

  • Mr. Herve HoppenotMr. Herve Hoppenot (Age 62)
    Chairman, Pres & CEO
    Comp: $2.36M
  • Ms. Christiana Stamoulis MBA (Age 51)
    Exec. VP & CFO
    Comp: $967.48k
  • Ms. Maria E. PasqualeMs. Maria E. Pasquale (Age 56)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $867.6k
  • Dr. Barry P. Flannelly M.B.A.Dr. Barry P. Flannelly M.B.A. (Age 64)
    MBA, Pharm.D., Exec. VP & GM of North America
    Comp: $842.85k
  • Dr. Steven H. SteinDr. Steven H. Stein (Age 55)
    Exec. VP & Chief Medical Officer
    Comp: $983.84k
  • Mr. Thomas Tray (Age 44)
    VP of Fin., Chief Accounting Officer & Controller
  • Mr. Michael James Morrissey (Age 58)
    Exec. VP & Head of Global Technical Operations
  • Dr. Dashyant Dhanak Ph.D. (Age 61)
    Exec. VP & Chief Scientific Officer
  • Ms. Christine Chiou
    Head of Investor Relations
  • Ms. Pamela M. Murphy (Age 71)
    VP of Investor Relations & Corp. Communications













INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2022?

11 Wall Street analysts have issued 1 year price targets for Incyte's stock. Their INCY share price forecasts range from $63.00 to $108.00. On average, they anticipate the company's share price to reach $84.92 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2022?

Incyte's stock was trading at $73.40 at the start of the year. Since then, INCY shares have decreased by 9.5% and is now trading at $66.44.
View the best growth stocks for 2022 here
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.61 by $0.24. The biopharmaceutical company had revenue of $911.40 million for the quarter, compared to the consensus estimate of $818.25 million. Incyte had a trailing twelve-month return on equity of 13.02% and a net margin of 28.46%. Incyte's quarterly revenue was up 29.1% compared to the same quarter last year. During the same period last year, the business earned $0.65 EPS.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include Dodge & Cox (9.02%), State Street Corp (4.25%), Renaissance Technologies LLC (2.31%), Price T Rowe Associates Inc. MD (1.53%), UBS Asset Management Americas Inc. (0.98%) and Northern Trust Corp (0.90%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $66.44.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $14.78 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $4.25 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,094 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.